Original Research ARTICLE
The role of insulin glargine and human insulin in the regulation of thyroid proliferation through mitogenic signaling
- 1School of Medicine, Zhejiang University, China
- 2Second Affiliated Hospital, School of Medicine, Zhejiang University, China
- 3First Affiliated Hospital, Zhejiang Chinese Medical University, China
- 4First Affiliated Hospital, College of Medicine, Zhejiang University, China
Our aim was to investigate whether human insulin (HI) or insulin glargine treatment could promote the proliferation of thyroid cells and determine the association between type 2 diabetes and thyroid disease. Rats were treated with different doses of HI and insulin glargine. Plasma glucose and the phosphorylation levels of the insulin receptor (IR), insulin-like growth factor 1 receptor (IGF-1R), protein kinase B (Akt), and extracellular signal-regulated kinase 1/2 (ERK1/2) were measured. A total of 105 rats were randomly assigned to three groups as follows: control group, HI group, and glargine group. Both drugs promoted the phosphorylation of IR, Akt, and ERK1/2 in a dose-dependent manner, and the effect of glargine persisted for longer period. Treatment with ultra-therapeutic doses of HI or glargine increased the expression of Ki-67 in thyroid cells. The results demonstrated that therapeutic doses of glargine have a longer-lasting hypoglycemic control than HI. Based on the results, HI or glargine did not stimulate thyroid cell proliferation at therapeutic doses, but high doses did.
Keywords: Insulin, Insulin receptor, Glargine, Thyroid disease, proliferation
Received: 14 Apr 2019;
Accepted: 13 Aug 2019.
Copyright: © 2019 Sheng, Shao, Yao, Tu, Zhang, Chen and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Dingguo Yao, First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310003, Zhejiang Province, China, email@example.com